ADPT — Adaptive Biotechnologies Income Statement
0.000.00%
Last trade - 00:00
- $685.75m
- $525.77m
- $170.28m
- 42
- 18
- 77
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 85.1 | 98.4 | 154 | 185 | 170 |
Cost of Revenue | |||||
Gross Profit | 62.8 | 75.9 | 105 | 127 | 94.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 163 | 251 | 363 | 385 | 397 |
Operating Profit | -78.4 | -153 | -209 | -200 | -227 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -68.6 | -146 | -207 | -200 | -225 |
Net Income After Taxes | -68.6 | -146 | -207 | -200 | -225 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -68.6 | -146 | -207 | -200 | -225 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -69.6 | -146 | -207 | -200 | -225 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.555 | -1.11 | -1.48 | -1.39 | -1.38 |